Royalty Report: Cancer, Medical, Therapeutic – Collection: 6521

“Applications” means US provisional applications
   1. US 61/113,809, entitled Utilization of Stents for the Treatment of Blood Borne Carcinomas; and
   2. US 61/160,755, entitled Sequential Extracorporeal Treatment of Blood.

A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.

Applications means
   a. PCT/US2009/064008, entitled Utilization of Stents for the Treatment of Blood Borne Carcinomas;
   b. PCT/US2010/027474, entitled Sequential Extracorporeal Treatment of Bodily Fluids;
and all applications of the United States and foreign countries that claim priority to the above PCT applications, including any non-provisional, continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof.

Licensed Products are products designed in the Field of Covid-19 Treatment (Covid-19 Licensed Products).

Issued Patents related to the patent applications
U.S. Patent 9,216,386 – Sequential extracorporeal treatment of bodily fluids
U.S. Patent 8,758,287 – Utilization of stents for the treatment of blood borne carcinomas

Intellectual Property shall mean any Confidential Information proprietary to the Disclosing Party and any trademark, service mark, trade name, invention, improvement, discovery, patent, patent application, trade secret, copyright, copyrightable work, trade dress, mask work, computer program or any other type of proprietary intellectual property to which the Disclosing party claims any rights, including any registrations or applications for registration or renewals of any of the foregoing, and all copies and tangible embodiments of the foregoing in whatever form or medium. Confidential information shall also mean any information not generally made available or known to the public and shall include, without limitation, all ideas, inventions, software, documentation, flowcharts, diagrams, improvements, discoveries, research and development, know how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, plans, specifications, and all other information or material within the definition of a “trade secret” as set forth in the Uniform Trade Secret Act, or which either party otherwise reasonably considers proprietary.

(COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

US Patent Number 5,101,072, Issued 3/3/1992

N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents

US Patent Number 5,214,068, Issued 5/25/1993

Sulfonylhydrazines and Their Use as Antineoplastic Agents and as Antitrypanosomal Agents

US Patent Number 5,256,820, Issued 10/26/1993

1-Alkyl-2-Acyl-1, 2-Disulfonylhydrazines

Additional Technologies

Antitumor 2-2 -aminocarbonyl -1-1, 2-bis (methylsulfonyl) -1-2-chloroethyl) ydrazines; (OCR 512)

2-Alkoxcarbonyl-and 2-aryloxycarbonyl -1, 2-bis (methylsulfonyl) – 1- (2chloroethyl) hyrazines with Antineoplastic Activity (OCR 524)

Synthesis of 3- and 5-methylaminopyridine-2 -carboxaldehyde Thiosemicarbazones (OCR 527)

Synthesis and Antitumor Active of 4- and 5-Substituted Derivatives of Isoquinoline-1-carboxaldehyde Thiosemicarbazone (OCR 528)

US Patent Application Serial Number 098,650

Novel L-2', 3'-Dideoxy Nucleoside Analogs as Anti-Hepatitis B (HBV) Agents

Additional Technology

Inhibition of Human Hepatitis B virus Replication by 3'-Thia 2', 3'-dideoxycytidine and its Derivatives (OCR 340)

Use of Porfiromycin, Dicoumoral, and X-irradiation for the treatment of solid tumors in Humans (CR 74)

Access to certain Data Concerning Clinical Studies carried out under the supervision of Yale faculty Concerning Porfiromycin

Licensed Products shall mean all products for therapeutic or diagnostic uses that may derive from or which result from the manufacture and production or use of a claim of the Licensed Patents, wherever sold.

Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.

Term Agreement lasts through expiration of last patent.

Territory Worldwide

5,101,072 The present invention is directed to novel sulfonylhydrazines and their use as antineoplastic agents. The present invention also concerns methylating agents, especially N-methyl-N- sulfonylhydrazines, and their use as antineoplastic and trypanocidal agents.  The present invention also relates to a method of treating cancer (e.g., leukemia, lymphoma, breast carcinoma, colon carcinoma and lung carcinoma), in a warm blooded animal patient, e.g., a human, by administering to such patient an antineoplastic effective amount of the aforesaid sulfonylhydrazine.

5,256,820 This invention generally concerns compounds having antineoplastic activity and methods of therapy using these compounds.

5,101,072 Sulfonylhydrazines of the formula RSO.sub.2 N(CH.sub.2 CH.sub.2 X)N(SO.sub.2 CH.sub.3).sub.2, wherein R is an alkyl or an aryl and X is a halogen or OSO.sub.2 Y, wherein Y is an alkyl or an aryl. Such sulfonylhydrazines are useful in treating cancer. Methylating agents of the formula (a) R'SO.sub.2 N(CH.sub.3)N(SO.sub.2 CH.sub.3).sub.2, wherein R' is an alkyl or an aryl and (b) R'SO.sub.2 N(CH.sub.3)N(CH.sub.3)SO.sub.2 R, wherein R is an alkyl or an aryl. Such methylating agents are useful as antitrypanosomal and anticancer agents.

5,256,820  Novel antineoplastic 1-alkyl-2-acyl-1,2-disulfonylhydrazine having the following formula and methods of therapy using those antineoplastic compounds ##STR1## where R.sub.1 and R.sub.2 are (independently) alkyl, cycloalkyl, aryl, aralkyl or heteroaryl. X is an acyl group, and Z is an alkyl or a haloalkyl group.

Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.